Compared to HC, csDMARD-only treated RA patients displayed significantly reduced proportions of IFNγ+CD4+ effector and memory T cells (Fig. 4A), IFNγ+CD8+ effector and TEMRA T cells (Fig. 4B), IL-17+CD4+ effector and memory T cells (Fig. 4C), and IL-17+CCR6+ Th17 cells (Fig. 4D). This evidence concerns the gene IL17A and rheumatoid arthritis.